M.D., Ph.D., VP Scientific & Medical Affairs, Molecular Health GmbH
Dr Armin Schneider has 20 years track record in leading roles in Biotech drug discovery and development and MD PhD from the University of Heidelberg, Germany. At Molecular Health, Armin pioneers the utilization of the company’s technology, Dataome® – a mighty clinical-molecular knowledge base of drugs, diseases and outcomes into machine learning applications and predictive algorithms to predict drug outcomes and R&D efficiency. He has authored over 150 publications and owns numerous patent families and has a strong background in neurology, pharmacology, molecular biology, and statistics, and specific interest in questions of applying advanced statistical methodology to drug development.
Predicting Drug Development Success with Machine Learning
We present a machine learning predictive engine to estimate likelihood of trial success (LOS) or approval of drug programmes (LOA) based on numerous and diverse feature domains powered by our clinico-molecular knowledge platform Dataome®. Molecular Health’s LOS/LOA Predictive Engine outperforms traditionally used retrospective statistic prediction.